ShihA, JacksonKC: Role of corticosteroids in palliative care. J Pain Palliat Care Pharmacother, 2007; 21:69–76.
2.
TwycrossR, Wilcock A (eds): Palliative Care Formulary, 3rd ed. Nottingham: Palliativedrugs, Ltd., 2007, pp. 362–368.
3.
Ericson-NielsenW: Steroids: Pharmacology, complications, and practice delivery issues. Ochsner J, 2014; 14:203–207.
4.
MundellL, LindemannR, DouglasJ, et al.: Monitoring long-term oral corticosteroids. BMJ Open Qual, 2017; 6:e000209.
5.
PiperJM, RayWA, DaughertyJR, et al.: Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med, 1991; 114:735–740.
6.
EllershawJE, KellyMJ: Corticosteroids and peptic ulceration. Palliat Med, 1994; 8:313–319.
7.
MagerDE, LinSX, BlumRA, et al.: Dose equivalency evaluation of major corticosteroids: pharmaokinetics and cell trafficking and cortisol dynamics. J Clin Pharmacol, 2003; 43:1216–1227.
BackI: Palliative Medicine Handbook, 3rd ed. 2001, Holme Tower Marie Curie Centre, Penarth, Wales, UK, pp. 126–129.
10.
YennurajalingamS, Frisbee-HumeS, PalmerJL, et al.: Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol, 2013; 31:3076–3082.
11.
Italian Group for Antiemetic Research: Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med, 1995; 332:1–5.
12.
Italian Group for Antiemetic Research: Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med, 2000; 342:1554–1559.
13.
InoueA, YamadaY, MatsumuraY, et al.: Randomized study of dexamethasone treatment for delayed emesis, anorexia and fatigue induced by irinotecan. Support Care Cancer, 2003; 11:528–532.
14.
Vayne-BossertP, HaywoodA, GoodP, et al.: Corticosteroids for adult patients with advanced cancer who have nausea and vomiting (not related to chemotherapy, radiotherapy, or surgery). Cochrane Database Syst Rev, 2017; 7:CD012002.
15.
YavuzşenT, DavisMP, WalshD, et al.: Systematic review of the treatment of cancer-associated anorexia and weight loss. J Clin Oncol, 2005; 23:8500–8511.
16.
BrueraE, RocaE, CedaroPL, et al.: Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep, 1985; 69:751–754.
17.
MaedaT, HayakawaT: Effectiveness of corticosteroid monotherapy for dyspnea relief in patients with terminal cancer. J Pain Palliat Care Pharmacother, 2017; 31:148–153.
18.
BarghiK, EdmondsKP, AjayiTA, AtayeeRS: Prescribing trends of palliative care team's use of dexamethasone for cancer-related pain. J Pain Palliat Care Pharmacother, 2018; 32:37–43.
19.
LussierD, HuskeyA, PortnoyR: Adjuvant analgesics in cancer pain management. Oncologist, 2004; 9:571–591.
20.
ChowE, MeyerRM, DingK, et al.: Dexamethasone in the prophylaxis of radiation-induced pain flare after palliative radiotherapy for bone metastases: a double-blind, randomised placebo-controlled, phase 3 trial. Lancet Oncol, 2015; 16:1463–1472.
21.
FeuerDJ, BroadleyKE: Systematic review and meta-analysis of corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancers. Ann Oncol, 1999; 10:1035–1041.
22.
SørensenS, Helweg-LarsenS, MouridsenH, HansenHH: Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomized trial. Eur J Cancer, 1994; 30A:22–27.
23.
GeorgeR, JebaJ, RamkumarG, et al.: Interventions for the treatment of metastatic extradural spinal cord compression in adults. Cochrane Database Syst Rev, 2015; 9:CD006716.
